Go Pro
→ Jon Najarian's #1 Energy Trade for 2026 (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:EPRX

Eupraxia Pharmaceuticals Q3 2024 Earnings Report

Eupraxia Pharmaceuticals logo
$7.45 +1.11 (+17.51%)
Closing price 04:00 PM Eastern
Extended Trading
$7.60 +0.15 (+2.01%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Eupraxia Pharmaceuticals EPS Results

Actual EPS
-$0.17
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Eupraxia Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eupraxia Pharmaceuticals Announcement Details

Quarter
Q3 2024
Date
11/7/2024
Time
After Market Closes
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Eupraxia Pharmaceuticals' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Eupraxia Pharmaceuticals' Q3 2024 Press ReleasePress Release

Eupraxia Pharmaceuticals Earnings Headlines

Brokerages Set Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Price Target at $18.00
September 2 at 1:45 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30997824
Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Stifel Nicolaus
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/EPRX-Q/pressreleases/3826256/eupraxia-pharmaceuticals-eprx-receives-a-buy-from-stifel-nicolaus/
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Chaikin Money Flow indicator has a new top retirement pick. The company holds three fast-growing businesses -- including an autonomous vehicle unit and a streaming service with 10x Netflix's reach -- any of which could be spun off in the next 12 to 24 months. It also pays a dividend, a rarity among high-growth AI names. Chaikin lays out the full case in a new free presentation, no email or credit card required.tc pixel
September 2 at 1:00 AM  |  Chaikin Analytics (Ad)
Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful ...
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69303756-eupraxia-pharmaceuticals-inc-eupraxia-pharmaceuticals-reports-symptom-response-data-from-its-ongoing-phase-1b-2a-resolve-trial-including-new-data-o-399.htm
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic ...
August 13, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/EPRX-T/pressreleases/3827638/eupraxia-pharmaceuticals-reports-symptom-response-data-from-its-ongoing-phase-1b2a-resolve-trial-including-new-data-on-odynophagia-painful-swallowing-in-eosinophilic-esophagitis-patients/
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344441/0/en/eupraxia-pharmaceuticals-reports-symptom-response-data-from-its-ongoing-phase-1b-2a-resolve-trial-including-new-data-on-odynophagia-painful-swallowing-in-eosinophilic-esophagitis-p.html
See More Eupraxia Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eupraxia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your email.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (NASDAQ:EPRX), Inc. (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline. The company has established preclinical programs targeting additional autoimmune indications and is preparing to initiate subsequent trials as it builds clinical proof-of-concept for its Treg-focused approach.

Eupraxia’s management team comprises seasoned professionals with expertise in immunology, drug development and regulatory affairs. The leadership is committed to leveraging decades of collective experience in biopharma to guide the company’s progression from early-stage research toward potential regulatory milestones and commercial readiness. As a publicly traded company on NASDAQ, Eupraxia Pharmaceuticals aims to deliver innovative, first-in-class treatments that address unmet medical needs in chronic immune-mediated conditions.

View Eupraxia Pharmaceuticals Profile
Earnings Tools